Evidence map›Paper›PMID 37860005›Full record

ArticleFrontiers in immunology2023

Editorial: Mitochondrial dysfunction in inflammation and autoimmunity.

Jens Staal, Luz Pamela Blanco, Andras Perl

Abstract readEditorial
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jens StaalUnit of Molecular Signal Transduction in Inflammation, Flemmish Institute of Biotechnology (VIB)-UGent Center for Inflammation Research, Ghent, Belgium.
Luz Pamela BlancoThe National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, United States.
Andras PerlDepartment of Medicine, Upstate Medical University, Syracuse, NY, United States.

Funding

SLE Treatment with N-acetylcysteineU01AR076092 · NIAMS · UPSTATE MEDICAL UNIVERSITY · PI Michael P McDermott, Andras Perl · 2020 to 2026
$7.9M
Metabolic Control of T-cell Lineage Specification in SLER01AI072648 · NIAID · UPSTATE MEDICAL UNIVERSITY · PI PERL, ANDRAS · 2008 to 2024
$6.1M
IMPACT OF HRES-1 ENDOGENOUS RETROVIRUS IN SLER01AI048079 · NIAID · UPSTATE MEDICAL UNIVERSITY · PI PERL, ANDRAS · 2000 to 2013
$2.7M
Endocytic Control of Autophagosome Formation in Lupus T cellsR01AI122176 · NIAID · UPSTATE MEDICAL UNIVERSITY · PI PERL, ANDRAS · 2016 to 2020
$2.0M
Treatment of SLE with N-acetylcysteineR01AT004332 · NCCIH · UPSTATE MEDICAL UNIVERSITY · PI PERL, ANDRAS · 2008 to 2011
$1.6M
Pathogenesis and Treatment of Liver Disease in Transaldolase DeficiencyR01DK078922 · NIDDK · UPSTATE MEDICAL UNIVERSITY · PI PERL, ANDRAS · 2010 to 2013
$1.4M
MOLECULAR BIOLOGY OF TRANSALDOLASER01DK049221 · NIDDK · UPSTATE MEDICAL UNIVERSITY · PI PERL, ANDRAS · 1996 to 2004
$904k
NCCIH NIH HHS R01 AT004332NIAID NIH HHS R01 AI048079NIAID NIH HHS R01 AI072648NIAID NIH HHS R01 AI122176NIAMS NIH HHS U01 AR076092NIDDK NIH HHS R01 DK049221NIDDK NIH HHS R01 DK078922
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AutoimmunityInflammationHumansMitochondriaReactive Oxygen SpeciesReactive Oxygen Speciesautoimmune diseasesDAMP (damage-associated molecular pattern)ferroptosisinflammationinterferonopathymetabolismmitochondriaROS - reactive oxygen species

Identifiers

PMID37860005
PMCPMC10582977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.